IMAB Share Price Performance
US$4.32
2.84 (191.89%)
Price US$4.32
Share PriceUS$4.32
I-Mab Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
IMAB Community Narratives
There are no narratives available yet.
Recent IMAB News & Updates
I-Mab Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.32
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
I-Mab Competitors
Snowflake Analysis
About IMAB
- Founded
- 2014
- Employees
- 32
- CEO
- WebsiteView website
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.2%
- 3 Months: 8.5%
- 1 Year: 17.7%
- Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. As for the past 12 months, the market is up 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›